“The Union Budget 2026 marks a pivotal moment for India’s healthcare ecosystem. For the first time, the government has moved decisively not just on infrastructure and technology, but also on medicine affordability, a critical concern for patients and clinicians alike. By waiving customs duty on 17 cancer drugs and exempting medicines for rare diseases, the budget directly addresses the cost burden of life-saving therapies and unlocks wider access for millions of Indians. This, coupled with initiatives aimed at lowering input costs and enabling domestic pharmaceutical production, sets the stage for more affordable treatment options across chronic and acute care pathways. **

Equally significant is the launch of the ₹10,000 crore Biopharma Shakti programme, which will accelerate advanced therapeutic manufacturing, research, and innovation in the biopharmaceutical sector. These measures complement the broader focus on capital investment, digital health integration, and workforce development, strengthening the foundation for quality care delivery at scale. **

While sector challenges such as cost pressures and financing access remain, Budget 2026 reflects real intent. With strong execution and collaborative partnerships, we can make high-quality, affordable healthcare a reality for all Indians.